Research Article

The Role of Albumin in Human Toxicology of Cobalt: Contribution from a Clinical Case

Simona Catalani,1 Roberto Leone,2 Maria Cristina Rizzetti,3 Alessandro Padovani,3 and Pietro Apostoli1

1Section of Occupational Health and Industrial Hygiene, Department of Experimental and Applied Medicine, University of Brescia, P.le Spedali Civili 1, 25123 Brescia, Italy
2Department of Public Health and Community Medicine, University of Verona, 37129 Verona, Italy
3Department of Medical and Surgical Sciences, Unit of Neurology, University of Brescia, 25123 Brescia, Italy

Correspondence should be addressed to Simona Catalani, catalani@med.unibs.it

Received 27 August 2010; Accepted 21 October 2010

Academic Editor: M. Ohsawa

Copyright © 2011 Simona Catalani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The distribution and adverse effects, especially to optic and acoustic nerves, of cobalt released from a hip arthroplasty and its association with albumin were studied. The analysis of cobalt was performed in plasma, whole blood, urine, and cerebrospinal fluid by inductively coupled plasma mass spectrometry (ICP-MS). The fraction of albumin binding the metal was determined by colorimetric assay using dithiothreitol (DTT). In all the biological matrices very high levels of cobalt were measured, but contrary to expected, a higher concentration in whole blood than in plasma was observed. The determination of altered albumin confirmed this hypothesis. This evidence might indicate an alteration in the binding of cobalt to albumin and a consequent increase in the concentration of the diffusible (free) fraction of the metal. This appears an interesting starting point for further investigations for identifying and better understanding cobalt neurotoxicity, apparently not so frequent in occupational medicine and clinical practice.

1. Introduction

Last year we reported the case of a 58-year-old woman with high concentration of cobalt released from her hip arthroplasty. The woman presented a selective II and VIII cranial nerves impairment and mild distal sensory-motor disturbances, and some months later she became definitely blind, severely deaf, and wheel-chair bounded due to severe limbs motor weakness [1].

During surgery of prosthesis removal of a massive infiltration of periprosthesis tissues by metallic debris (metallosis) became evident.

The patient has undergone chelation therapy with ethylenediaminetetraacetic acid (EDTA) in order to reduce the cobalt body burden.

In the scientific literature there are only five other cases of severe adverse effects on nervous system associated with cobalt released from prosthesis [2–6].

Moreover, cobalt neurotoxicity for acoustic and optic nerves has been reported following occupational exposures to the metal [7, 8] or, few decades ago, after oral intake during therapy of refractory anaemia [9–11].

Cobalt concentrations in biological fluids have been investigated in subjects with prosthesis [12–14], but the kinetics of released metal ions is not adequately known, due to the lack of information about amount and rate of release from hip surface, about the solubility of released ions and or about the fraction phagocyted by macrophages and the role of metal deposition-storage mechanisms [15–17].

The distribution of cobalt in the body is also influenced by binding to the plasma proteins. Albumin has been indicated to be a physiological carrier of cobalt ions in old and more recent studies [18, 19].

The cobalt binding to albumin has been studied because the base of the “Albumin Cobalt Binding test” (ACB test) approved by the Food and Drug Administration for evaluating myocardial ischemia.
Ischemia modified albumin (IMA) is a form of human serum albumin in which the N-terminal amino acids have been altered so as to be unable to bind transition metals [20].

However, other pathologies such as trauma, scleroderma, diabetes, bacterial or viral infections, end-stage renal disease, liver cirrhosis, brain ischemia, peripheral arterial disease, and cancer are able to influence the binding site of cobalt in albumin [21–26]. In addition there are also evidences of possible genetic variants of human serum albumin, particularly structural changes at the N-terminus abolish transition metals binding [27, 28].

The direct measurement of cobalt levels in biological matrices and protein binding of this clinical case may be useful in understanding effects and variability of cobalt neurotoxicity.

2. Material and Methods

2.1. Cobalt Analysis. Cobalt in blood, plasma, urine, and cephalorachidian fluid was measured using an inductively coupled-plasma mass spectrometry (ICP-MS, ELAN DRCII, Perkin Elmer, Waltham, USA) equipped with Dynamic Cell Reaction. The detailed method is described in a our previous paper [29].

The samples of plasma and blood were diluted with Triton X-100 0.05%, while for urine and cephalorachidian fluid was used bidistilled water, tracepur for inorganic trace analysis (Merck KgaA). The calibration standards were prepared by standard solutions of single elements ranging from 0.5 µg/L to 1000 µg/L cobalt (in HNO₃ 2% mono elemental standard solution Carlo Erba Reagenti, Milano, Italy).

The accuracy of the method was assessed using specific certified materials for different matrices 1A/B (blood samples), 11A/B (plasma) 2A/B (urine), all from the German Society of Occupational and Environmental Medicine (Erlangen, Germany). The sample solutions were pumped in the spray chamber by a peristaltic pump detecting mass 59(Co).

The accuracy of methods for the determination of cobalt in blood and urine was 95%, whereas it was 97% for plasma. Method precision was 6.1 and 6.9% for blood and plasma determinations, respectively, whereas in the case of urine precision was 4.1%. For each matrix, the LODs were determined as three SD of the background signal. The LOD was 0.02 µg/L for Co–B and Co–P, and 0.05 µg/L for Co–U.

2.2. IMA Determination. The concentration of IMA can be determined by addition of known amount of cobalt to serum or plasma specimen and measurement of the unbound cobalt by colorimetric assay [20, 23, 30–32].

To remove the interference of EDTA, the plasma was pretreated with calcium chloride (CaCl₂ 2H₂O; Sigma-Aldrich); the combination of sample and reagent pretreatment was then centrifugated at 1000–1200 g for 10 minutes without mixing the two components [33].

Plasma was incubated with a cobalt chloride solution (Sigma-Aldrich, CoCl₂·6H₂O; 1 g/L, 10 minutes) and dithiothreitol (Sigma-Aldrich; 1.5 g/L, 2 minutes) before dilution in saline solution (0.9% NaCl) and measurement at 470 nm in a spectrophotometer (UV-Vis spectrophotometer Cary 50, Varian, Palo Alto, USA). IMA was calculated from the difference between samples measured with and without dithiothreitol and reported in mean absorbance units (ABSU). Bar-Or et al. [31] showed that values greater than 0.400 ABSU indicate lower cobalt binding and values equal or lower than 0.400 ABSU higher cobalt binding.

2.3. Statistical Analysis. Data were analyzed by the SPSS 16.0 for Windows statistical package.

The distributions, assessed by the one-sample Kolmogorov-Smirnov test, were normal for plasmatic and hematic cobalt in controls and for IMA in both groups.

The trend of cobalt distribution in woman’s plasma and blood and in CoB/CoP ratio was assessed by Ordinary Least Square (OLS).

The range of repeated measures of cobalt concentrations, ratio CoB/CoP and IMA in woman with prostesis were compared with the arithmetic means of healthy and unexposed subjects.

3. Results and Discussion

Trend of plasma, whole blood, and urine cobalt concentrations are reported in Figures 1 and 2. Cobalt basal levels were very high (549 µg/L in whole blood; 260 µg/L in plasma), after the chelation therapy the levels decreased by 70% in whole blood and 61% in plasma. A further reduction occurs after the prosthesis removal (94 µg/L in whole blood and 64 µg/L in plasma).

The current (14 months after removal) cobalt levels remained higher than reference values (33.9 versus 0.05–2.7 µg/L in blood; 28.5 versus 0.1–0.6 µg/L in plasma).
Figure 2: Levels of cobalt in urine (CoU) in µg/L in woman with prosthesis. The normal values are 0.1–1.5 µg/L.

Table 1: Ratio of whole blood cobalt (CoB)/plasma cobalt (CoP) in present study (repeated measures), workers exposed to cobalt, and ratio reported in a study of Walter et al. [34]. mean ± standard deviation.

|          | N° CoB/CoP | CoB (µg/L) | CoP (µg/L) |
|----------|------------|------------|------------|
| Present study | 61         | 1.73 ± 0.38 | 196.12 ± 134.45 | 106.36 ± 57.49 |
| Workers exposed to cobalt | 23         | 0.90 ± 0.40 | 3.20 ± 1.52 | 3.86 ± 1.84 |
| Walter et al., [34] | 29         | 0.82 | |

In the urine cobalt was rapidly and in great extent eliminated after a chelation therapy, the rate of excretion was 2173 µg/L and stabilized around 200 µg/L after prosthesis removal.

The cobalt in the cephalorachidian fluid was determined before chelation and removal of the prosthesis (11.4 µg/L and 10.1 µg/L) and two days after (5.4 and 2.6 µg/L); the normal values ranged between 0.05–0.15 µg/L.

In spite of these high levels a clear improvement of clinical evidence for most adverse effects to nervous system, except the visual function, was seen.

The investigation of cobalt distribution in blood fractions showed, contrary to the expected, that most of the cobalt was in whole blood than in plasma.

Normally most of the cobalt is found in the serum and plasma with lower concentrations in the red blood cells (RBC); the whole blood levels are between those of the RBCs and the plasmatic fraction [34].

The ratio CoB/CoP is different when considering different kind of metal exposures, in Table 1 were reported the ratio of workers exposed to cobalt during hard metals production (unpublished data) and a collection of samples from patients after hip arthroplasty [34].

A greater distribution of cobalt in whole blood than in plasma may indicate an alteration in the binding of cobalt to plasma proteins and an increased concentration of nonprotein-bound cobalt.

IMA was measured in different samples of patients in study and in healthy unexposed subjects, IMA values significantly higher than controls seem to confirm this hypothesis (Figure 3).

According to Bar-Or [31] the absorbance units (ABSU) greater than 0.4 indicate a reduced cobalt binding to albumin.

IMA’s values and ratio of CoB/CoP showed a good correlation ($r^2 = 0.6325$) (Figure 4); on the contrary, no correlation has been demonstrated between the values of IMA and the concentrations of cobalt in blood or in plasma.

Cobalt in blood and plasma follows a defined decreasing trend while the ratio of CoB/CoP does not follow any specific trend.

Critical points of this hypothesis have been considered; the possibility that in our conditions the albumin binding site could be only saturated by high amount of cobalt and not altered is disproved by the fact that altered albumin (IMA 0.92 and 1.17 ABSU) corresponds both to high and lower cobalt blood concentrations (415 and 38 µg/L, resp.), excluding a possible interference of cobalt concentration on colorimetric measure.
The percentage of blood albumin on total proteins was monitored during the hospitalization period and was 55.68 ± 9.57% (normal range of laboratory 55–69%).

The alteration of N-terminal binding site of human albumin may be the cause of the reversed CoB/CoP ratio and the consequent greater amount of cobalt in an available form for higher distribution and interaction into the cells.

Nonprotein-bound metal can enter cells through a promiscuous metal transporter, divalent metal transporter 1 (DMT1) [35, 36], that is known to actively transport iron, zinc, manganese, cobalt, cadmium, copper, and lead, via a proton-coupled mechanism [37]. DMT1 is predicted to have 12 transmembrane segments and to be expressed in neurons, allowing the incorporation of metals from the extracellular environment and/or from the recycling endosomes.

Howitt et al. [38] showed that human neurons in culture were susceptible to metal toxicity in cellular assays involving increasing concentrations of environmental iron and cobalt. They have identified DMT1 as the key player in the entry of metal ions in the brain.

In our case an high concentration of free cobalt in the whole blood could be available to interact with DMT1 and becoming the cause of the neurological effects.

The concentration of cobalt in cerebrospinal fluid measured before chelation and before prosthesis removal showed a massive amount of cobalt (11.4 μg/L), that corresponds to a 2.37 CoB/CoP ratio.

An alteration of the bound with the main plasma protein resulting in a greater amount of free cobalt may be the cause of the not frequently neurologic symptoms reported in the scientific literature for cobalt intoxication.

Some authors suggest that the alteration of binding site of albumin could be the result of acidosis, reduced oxygen tension, and the generation of free radicals [39, 40] and this conditions could be caused by cobalt and chromium constantly released from the prosthesis.

In addition genetic variants of human serum albumin have been reported, each of these variants has been classified on the basis of the structural changes at the N-terminus that abolish transition metal binding [41].

Another aspect to consider is the possible influence of diabetes. Our patient implanted with hip prosthesis was suffering from type 2 diabetes.

Many authors reported higher levels of IMA in diabetic patients, and they suggest that the plasmatic albumin of diabetic patients was modified for the chronic hypoxia conditions provoked mainly by hyperglycemia and oxidative stress in diabetes [25, 41].

Ukinc et al. [42] reported that diabetic patients without cardiovascular disease have a higher serum IMA levels compared to healthy controls.

Diabetes may have been a contributory cause of the alteration of albumin that in the state of cobalt intoxication was not able to correctly bound it favoring the increase in the haematic fraction.

4. Conclusion

Among all the patients with extremely high cobalt concentrations in blood or urine, only few develop a severe neurologic syndrome. The reason is still unclear and, even if it is certain that cobalt can cause potential serious effects on human central nervous system, little is known about the mechanisms through which this metal can cause neurotoxicity to optic and acoustic nerves.

We have tried to explain the anomalous reaction to cobalt in different ways and an alteration of plasma protein with a consequent more active fraction seems to be the most plausible hypothesis for the neurological symptoms.

A possible explanation for the symptoms may be the altered albumin binding capacity and the consequent increase of the free form of cobalt in the blood.

The decreased linkage to albumin for cobalt generates IMA and increases the concentration of biologically active free cobalt. The free cobalt can then interact with specific protein carriers to the cellular targets of the central nervous system.

The cause of albumin alteration is not clear, we hypothesize an influence of several factors, which in this specific situation are the generation of free radicals by cobalt, a genetic predisposition or a possible influence of diabetes.

We hope that our study can be the starting point for further studies on the neurological effects related to the toxicity of cobalt.

References

[1] M. C. Rizzetti, P. Liberini, G. Zarattini et al., “Loss of sight and sound. Could it be the hip?” The Lancet, vol. 373, no. 9668, p. 1052, 2009.
[2] S. Megaterio, G. Galetto, E. Alossa, and S. Capretto, “Sistemici effects of ionic release in wear of prosthetic head: a case report,” Giorn It Ort Traum, vol. 27, pp. 173–175, 2001.
[3] W. Steens, J. F. Loehr, G. Von Feserst, and A. Katzer, “Chronic cobalt poisoning in endoprothetic replacement,” Orthopade, vol. 35, no. 8, pp. 860–864, 2006.
[4] M. Oldenburg, R. Wegner, and X. Baur, “Severe cobalt intoxication due to prosthesis wear in repeated total hip arthroplasty,” Journal of Arthroplasty, vol. 24, no. 5, pp. 825–e15, 2009.
[5] S. S. Tower, “Cobalt toxicity in two hip replacement patients,” Epidemiology Bulletin No. 14, 2010, http://www.epi.alaska.gov/bulletins/docs/b2010_14.pdf.
[6] T. Ikeda, K. Takahashi, T. Kabata, D. Sakagoshi, K. Tomita, and M. Yamada, “Polyneuropathy caused by cobalt-chromium metallosis after total hip replacement,” Muscle and Nerve, vol. 42, no. 1, pp. 140–143, 2010.
[7] C. Jordan, R. D. Whitman, M. Harbut, and B. Tanner, “Memory deficits in workers suffering from hard metal disease,” Toxicology Letters, vol. 54, no. 2–3, pp. 241–243, 1990.
[8] H. M. Meecham and P. Humphrey, “Industrial exposure to cobalt causing optic atrophy and nerve deafness: a case report,” Journal of Neurology Neurosurgery and Psychiatry, vol. 54, no. 4, pp. 374–375, 1991.
[9] F. H. Gardner, “The use of cobaltous chloride in the anemia associated with chronic renal disease,” The Journal of Laboratory and Clinical Medicine, vol. 41, no. 1, pp. 56–64, 1953.
[10] U. O. Schirrmacher, “Case of cobalt poisoning,” British Medical Journal, vol. 1, no. 539, pp. 544–545, 1967.
[11] A. Licht, M. Oliver, and E. A. Rachmilewitz, “Optic atrophy following treatment with cobalt chloride in a patient with pancycopenia and hypercellular marrow,” Israel Journal of Medical Sciences, vol. 8, no. 1, pp. 61–66, 1972.
[12] F. W. Sunderland Jr., S. M. Hopfer, T. Swift et al., “Cobalt, chromium, and nickel concentrations in body fluids of patients with porous-coated knee or hip prostheses,” Journal of Orthopaedic Research, vol. 7, no. 3, pp. 307–315, 1989.
[13] P.-A. Vendittioli, M. Ganapathi, and M. Lavigne, “Blood and urine metal ion levels in young and active patients after Birmingham hip resurfacing arthroplasty,” Journal of Bone and Joint Surgery. British, vol. 89, no. 7, p. 989, 2007.
[14] A. Grüb, M. Marker, W. Brodner et al., “Long-term follow-up of metal-on-metal total hip replacement,” Journal of Orthopaedic Research, vol. 25, no. 7, pp. 841–848, 2007.
[15] R. F. Coleman, J. Herrington, and J. T. Scales, “Concentration of wear products in hair, blood, and urine after total hip replacement,” British medical journal, vol. 1, no. 5852, pp. 527–529, 1973.
[16] C. P. Case, V. G. Langkamer, C. James et al., “Widespread dissemination of metal debris from implants,” Journal of Bone and Joint Surgery. British, vol. 76, no. 5, pp. 701–712, 1994.
[17] R. M. Urban, J. J. Jacobs, M. J. Tomlinson, J. Gavrilovic, J. Black, and M. Peoch, “Dissemination of wear particles to the liver, spleen, and abdominal lymph nodes of patients with hip or knee replacement,” Journal of Bone and Joint Surgery. American, vol. 82, no. 4, pp. 457–477, 2000.
[18] M. S. N. Rao and H. Lal, “Metal protein interactions in buffer solutions. Part II. A polarographic study of the interaction of ZnII and CdII with bovine serum albumin,” Journal of the American Chemical Society, vol. 80, no. 13, pp. 3222–3226, 1958.
[19] Y. N. Ordóñez, M. Montes-Bayón, E. Blanco-González et al., “Metal release in patients with total hip arthroplasty by DF-ICP-MS and their association to serum proteins,” Journal of Analytical Atomic Spectrometry, vol. 24, no. 8, pp. 1037–1043, 2009.
[20] D. Bar-Or, L. T. Rael, E. P. Lau et al., “An analog of the human albumin N-terminus (Aspa-Ala-His-Lys) prevents formation of copper-induced reactive oxygen species,” Biochemical and Biophysical Research Communications, vol. 284, no. 3, pp. 856–862, 2001.
[21] G. Lipps, G. Brocco, G. L. Salvagno, M. Montagnana, F. Dima, and G. C. Guidi, “High-workload endurance training may increase serum ischemia-modified albumin concentrations,” Clinical Chemistry and Laboratory Medicine, vol. 43, no. 7, pp. 741–744, 2005.
[22] G. Lipps, M. Montagnana, G. L. Salvagno, and G. C. Guidi, “Potential value for new diagnostic markers in the early recognition of acute coronary syndromes,” Canadian Journal of Emergency Medicine, vol. 8, no. 1, pp. 27–31, 2006.
[23] G. Lipps, M. Montagnana, G. L. Salvagno, and G. C. Guidi, “Standardization of ischemia-modified albumin testing: adjustment for serum albumin,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 2, pp. 261–262, 2007.
[24] M. Montagnana, G. Lipps, A. Volpe et al., “Evaluation of cardiac laboratory markers in patients with systemic sclerosis,” Clinical Biochemistry, vol. 39, no. 9, pp. 913–917, 2006.
[25] A. Piwowar, M. Knapik-Kordecka, and M. Warwas, “Ischemia-modified albumin level in type 2 diabetes mellitus—preliminary report,” Disease Markers, vol. 24, no. 6, pp. 311–317, 2008.
[26] R. Govender, J. De Greef, R. Delport, P. J. Becker, and W. J. H. Vermaak, “Biological variation of ischaemia-modified albumin in healthy subjects,” Cardiovascular Journal of Africa, vol. 19, no. 3, pp. 141–144, 2008.
[27] J. M. Sheat, R. J. Peach, and P. M. George, “Rapid detection and initial characterization of genetic variants of human serum albumin,” Clinical Chemistry, vol. 37, no. 7, pp. 1221–1224, 1991.
[28] N. V. Bhagavan, E. M. Lai, P. A. Rios et al., “Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction,” Clinical Chemistry, vol. 49, no. 4, pp. 581–583, 2003.
[29] G. De Palma, P. Manini, M. Sarnico, S. Molinari, and P. Apostoli, “Biological monitoring of tungsten (and cobalt) in workers of a hard metal alloy industry,” International Archives of Occupational and Environmental Health, vol. 83, pp. 173–181, 2010.
[30] P. Apostoli, S. Porru, P. Duca, A. Ferioli, and L. Alessio, “Significance and validity of a shortened lead chelation test,” Journal of Occupational Medicine, vol. 32, no. 11, pp. 1124–1129, 1990.
[31] D. Bar-Or, E. Lau, and J. V. Winkler, “A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report,” Journal of Emergency Medicine, vol. 19, no. 4, pp. 311–315, 2000.
[32] D. Bar-Or, L. T. Rael, L. Bar-Or et al., “The cobalt-albumin binding assay: insights into its mode of action,” Clinica Chimica Acta, vol. 387, no. 1-2, pp. 120–127, 2008.
[33] G. J. Fagan, H. Waymert, D. L. Morris, and P. A. Crosby, “The albumin cobalt binding test: analytical performance of a new automated chemistry assay for the detection of ischemia modified albumin (IMA36),” Journal of Clinical Ligand Assay, vol. 25, no. 2, pp. 178–187, 2002.
[34] L. R. Walter, E. Marei, R. Harbury, and J. Weaver, “Distribution of chromium and cobalt ions in various blood fractions after resurfacing hip arthroplasty,” Journal of Arthroplasty, vol. 23, no. 6, pp. 814–821, 2008.
[35] V. Picard, G. Govoni, N. Jabado, and P. Gross, “Nramp 2 (DCT1/DMT1) expressed at the plasma membrane transports iron and other diveral cations into a calcine-accessible cytoplasmic pool,” Journal of Biological Chemistry, vol. 275, no. 46, pp. 35738–35745, 2000.
[36] J. R. Forbes and P. Gros, “Iron, manganese, and cobalt transport by Nramp1 (Slc11a1) and Nramp2 (Slc11a2) expressed at the plasma membrane,” Blood, vol. 102, no. 5, pp. 1884–1892, 2003.
[37] H. Gunshin, B. Mackenzie, U. V. Berger et al., “Cloning and characterization of a mammalian proton-coupled metal-ion transporter,” Nature, vol. 388, no. 6641, pp. 482–488, 1997.
[38] J. Howitt, U. Putz, J. Lackovic et al., “Divalent metal transporter 1 (DMT1) regulation by Ndfip1 prevents metal toxicity in human neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 36, pp. 15489–15494, 2009.
[39] S. Turedi, A. Gunduz, A. Mentese et al., “Investigation of the possibility of using ischemia-modified albumin as a novel and early prognostic marker in cardiac arrest patients after cardiopulmonary resuscitation,” Resuscitation, vol. 80, no. 9, pp. 994–999, 2009.
[40] A. Gunduz, S. Turedi, A. Mentese et al., “Ischemia-modified albumin levels in cerebrovascular accidents,” American Journal of Emergency Medicine, vol. 26, no. 8, pp. 874–878, 2008.
[41] M. Kaefer, S. J. Piva, J. A.M. De Carvalho et al., “Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus,” Clinical Biochemistry, vol. 43, no. 4-5, pp. 450–454, 2010.

[42] K. Ukinc, S. Eminagaoglu, H. O. Ersoz et al., “A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin,” Endocrine, vol. 36, no. 3, pp. 425–432, 2009.
Submit your manuscripts at
http://www.hindawi.com